

SUPPLEMENTARY TABLE 2. Demographic characteristics and clinical outcomes of infants aged <6 months hospitalized with laboratory-confirmed SARS-CoV-2 by maternal vaccination status,* excluding birth hospitalizations[†]— COVID-NET, 12 states, [§] October 2022–April 2024

Characteristic	No record of maternal vaccination		Maternal vaccination during pregnancy		p-value
	No.	Weighted % [¶] (95% CI)	No.	Weighted % [¶] (95% CI)	
Total no. of hospitalized infants	921	87.5 (85.3–89.5)	144	12.5 (10.5–14.7)	—
Age					
Median age, days median (IQR)	—	58 (28–114)	—	109 (56–145)	<0.01
<1 month	249	28.2 (24.8–31.8)	21	14.3 (9.0–21.2)	<0.01
1–2 months	343	36.4 (33.0–40.0)	36	25.8 (18.5–34.2)	
3–5 months	329	35.3 (31.8–38.9)	87	60.0 (51.1–68.4)	
Sex					
Male	550	58.5 (54.7–62.1)	92	64.1 (55.4–72.2)	0.23
Female	371	41.5 (37.9–45.3)	52	35.9 (27.8–44.6)	
Race and Ethnicity**					
White, non-Hispanic	312	32.7 (29.4–36.2)	58	40.3 (31.9–49.1)	0.43
Hispanic	305	33.7 (30.2–37.3)	49	33.6 (25.8–42.2)	
Black, non-Hispanic	156	17.6 (14.7–20.7)	21	13.6 (8.4–20.3)	
Asian, non-Hispanic	55	6.0 (4.4–8.1)	4	2.6 (0.7–6.7)	
Persons of all other races	35	3.8 (2.6–5.4)	7	4.60 (1.8–9.4)	
Unknown race or ethnicity	58	6.1 (4.6–8.0)	5	5.4 (1.2–14.5)	
Underlying Conditions					
No underlying medical conditions	692	76.8 (73.7–79.7)	103	69.9 (60.9–77.9)	0.10
Any underlying medical conditions ^{††}	229	23.2 (20.3–26.3)	41	30.1 (22.1–39.7)	0.10
Prematurity (gestational age <37 weeks)	161	17.3 (14.6–20.3)	20	14.2 (8.8–21.2)	0.37
Cardiovascular disease, including congenital heart disease	58	6.0 (4.5–7.9)	12	10.2 (4.6–18.7)	0.14
Chronic lung disease ^{§§}	49	5.0 (3.6–6.7)	5	3.2 (1.0–7.6)	0.34
Neurologic disorders	24	2.8 (1.7–4.3)	7	6.7 (2.1–15.5)	0.08
Season					
October 2022–September 2023	613	82.4 (79.4–85.1)	132	17.6 (14.9–20.6)	<0.01
October 2023–April 2024	308	95.7 (92.0–98.0)	12	4.3 (2.0–8.0)	
COVID-19 related symptoms on admission^{¶¶}					
Yes	866	93.3 (91.2–95.1)	132	91.3 (85.1–95.5)	0.41
Hospitalization intervention/outcome					
Length of hospital stay, days median (IQR)	921	2 (1–3)	144	2 (1–4)	0.94
ICU admission	216	22.5 (19.6–25.6)	32	23.0 (15.7–31.7)	0.90
In-hospital death	8	0.8 (0.3–0.6)	0	—	
Highest level of oxygen support received during hospitalization					
Supplemental oxygen	199	22.9 (19.6–26.5)	36	24.0 (17.3–31.9)	0.77

High flow nasal canula or BiPAP/CPAP	203	21.7 (18.8–24.8)	28	21.8 (14.4–31.0)	0.97
Invasive mechanical ventilation	45	4.6 (3.3–6.3)	6	3.9 (1.4–8.4)	0.66

Abbreviations: BiPAP/CPAP = bilevel positive airway pressure/continuous positive airway pressure; ICU = intensive care unit.

* Maternal vaccination status was unknown for 83 (7.4%) infants; these infants were excluded from maternal vaccination status. Proportions presented are calculated from among those with known vaccination status (n = 1,065).

† A birth hospitalization was defined as the hospitalization during which the infant was born.

§ Selected counties in California, Colorado, Connecticut, Georgia, Maryland, Michigan, Minnesota, New Mexico, New York, Oregon, Tennessee, and Utah.

¶ Data are from a weighted sample of hospitalized children with completed medical record abstractions. Sample sizes presented are unweighted with weighted percentages.

** If ethnicity was unknown, non-Hispanic ethnicity was assumed. Persons of Hispanic or Latino (Hispanic) origin might be of any race but are categorized as Hispanic; all racial groups are non-Hispanic. Persons of all other races include non-Hispanic American Indian or Alaska Native and multiracial persons.

†† Defined as one or more of the following: prematurity, neurologic disorders, cardiovascular disease including congenital heart disease, chronic metabolic disease, immunosuppressive condition, chronic lung disease of prematurity/bronchopulmonary dysplasia, asthma/reactive airway disease or airway abnormality, blood disorder, gastrointestinal disease, renal disease, genetic disorder, or other underlying condition.

§§ For infants <6 months, chronic lung disease includes bronchopulmonary dysplasia and chronic lung disease of prematurity. Does not include asthma or reactive airway disease.

¶¶ COVID-19–related symptoms included respiratory conditions (congestion/runny nose, cough, shortness of breath/respiratory distress, upper respiratory infection, wheezing, nausea/vomiting, rash, and seizures) and non-respiratory conditions (conjunctivitis, diarrhea, fever, apnea, cyanosis, decreased vocalization/stridor, dehydration, hypothermia, inability to eat/poor feeding, and lethargy). Signs and symptoms data were abstracted from medical charts and might be incomplete.